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Background.  The incidence of herpes zoster is up to 9 times higher in immunosuppressed solid organ transplant recipients than 
in the general population. We investigated the immunogenicity and safety of an adjuvanted recombinant zoster vaccine (RZV) in 
renal transplant (RT) recipients ≥18 years of age receiving daily immunosuppressive therapy.
Methods. In this phase 3, randomized (1:1), observer-blind, multicenter trial, RT recipients were enrolled and received 2 doses 
of RZV or placebo 1–2 months (M) apart 4–18M posttransplant. Anti–glycoprotein E (gE) antibody concentrations, gE-specific CD4 
T-cell frequencies, and vaccine response rates were assessed at 1M post–dose 1, and 1M and 12M post–dose 2. Solicited and unso-
licited adverse events (AEs) were recorded for 7 and 30 days after each dose, respectively. Solicited general symptoms and unsolic-
ited AEs were also collected 7 days before first vaccination. Serious AEs (including biopsy-proven allograft rejections) and potential 
immune-mediated diseases (pIMDs) were recorded up to 12M post–dose 2.
Results. Two hundred sixty-four participants (RZV: 132; placebo: 132) were enrolled between March 2014 and April 2017. gE-spe-
cific humoral and cell-mediated immune responses were higher in RZV than placebo recipients across postvaccination time points 
and persisted above prevaccination baseline 12M post–dose 2. Local AEs were reported more frequently by RZV than placebo recipi-
ents. Overall occurrences of renal function changes, rejections, unsolicited AEs, serious AEs, and pIMDs were similar between groups.
Conclusions. RZV was immunogenic in chronically immunosuppressed RT recipients. Immunogenicity persisted through 12M 
postvaccination. No safety concerns arose.
clinical Trials Registration. NCT02058589.
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Herpes zoster (HZ) results from reactivation of latent varicella 
zoster virus (VZV), and usually presents as a painful dermato-
mal rash [1]. The most common complication of HZ is posther-
petic neuralgia, chronic pain that can persist for months or even 
years after resolution of the zoster rash [2].
Diminished cellular immunity to VZV increases the risk of HZ [3]. 
Compared to healthy individuals, persons with impaired cellular im-
munity, especially those receiving immunosuppressive therapies after 
organ transplantation, are at increased risk of developing HZ [4–10]. 
In particular, solid organ transplant (SOT) patients have a mixed, but 
mainly cellular immune deficit, induced by chronic immunosuppres-
sive therapy required to prevent organ rejection.
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The observed HZ incidence rates in SOT recipients [4–6] are 
up to 9 times higher compared with those in the general pop-
ulation (22–28 vs 3–5/1000 person-years, respectively) [7, 8]. 
However, HZ incidence varies depending on the type of trans-
planted organ [6].
Although efficacy of vaccines in SOT recipients is often sub-
optimal, immunization against common infectious diseases is 
currently recommended for SOT candidates and recipients to 
reduce the risk of infections [9]. While infection may stimulate 
the immune system, leading to an increased risk of rejection 
[11], there is very limited evidence of a correlation between vac-
cination and allograft rejection. Nevertheless, this remains a ge-
neral concern for transplant physicians [9, 12].
Currently, 2 vaccines are licensed for the prevention of HZ in 
different regions worldwide. The live attenuated zoster vaccine 
(Zostavax) is, however, contraindicated in immunosuppressed 
individuals, including SOT recipients [13].
The adjuvanted recombinant zoster vaccine (RZV; Shingrix) 
is a nonlive vaccine that consists of a truncated form of VZV 
glycoprotein E (gE) and the GSK AS01B Adjuvant System. RZV 
is licensed for the prevention of HZ and postherpetic neuralgia 
in adults ≥50 years of age [14, 15]; it is highly immunogenic 
and demonstrated >90% efficacy against HZ in all age groups 
among adults aged ≥50 years, 68% efficacy in autologous he-
matopoietic stem cell transplant (HSCT) recipients ≥18 years of 
age, and 87% efficacy in a post hoc analysis in patients ≥18 years 
of age with hematologic malignancies. The safety profile of RZV 
was clinically acceptable in these populations [14–20].
In this study, we evaluated the immunogenicity and safety of 
RZV in renal transplant (RT) patients ≥18 years of age receiving 
daily immunosuppressive therapy. As the transplant commu-
nity has a long-established renal allograft monitoring program 
and because the immunosuppressive therapies used for RTs are 
also used for other SOTs, RT was selected as a model for SOTs.
METHODS
Study Design and Participants
This was a phase 3, randomized, observer-blind, placebo-con-
trolled, multicenter trial, conducted in 9 countries (Belgium, 
Canada, Czech Republic, Finland, Italy, Panama, Republic 
of Korea, Spain, and Taiwan) between March 2014 and April 
2017. RT recipients were randomized 1:1 to receive 2 doses of 
RZV or placebo 1–2 months (M) apart, at visits defined as M0 
and M1 visits. The randomization algorithm included the fol-
lowing minimization factors: age (18–29, 30–49, or ≥50 years), 
gender, participant’s highest panel reactive antibody (PRA) or 
calculated PRA (cPRA) score at/prior to transplant, and main-
tenance immunosuppressive therapy (use of mycophenolate 
compounds, calcineurin inhibitors or sirolimus, or corticoste-
roids). RT patients ≥18 years of age were eligible for partic-
ipation at 4–18M posttransplantation if they had received an 
ABO-compatible allograft, had stable renal function, and were 
free of any allograft rejection in the 3M preceding the first 
vaccination.
RT recipients were excluded from participation if they had a 
primary kidney disease (PKD) known to have a high incidence 
of recurrence, a previous allograft loss due to recurrent PKD, 
multiple organs transplanted, or a condition that could interfere 
with study-required evaluations. Persons were also excluded if 
they had any systemic autoimmune or potential immune-me-
diated disease (pIMD) listed in Supplementary Table 1 (excep-
tions are listed in the Supplementary Text 1B), had clinical 
history of HZ or varicella, or received HZ/varicella vaccination 
within the 12M preceding the first dose of study vaccine/pla-
cebo. The full list of inclusion and exclusion criteria is provided 
in Supplementary Text 1.
All participants provided written informed consent at en-
rollment. The study protocol was reviewed and approved by 
independent ethics committees or institutional review boards. 
The study was conducted in accordance with the Declaration 
of Helsinki and the principles of Good Clinical Practice. The 
study is registered at ClinicalTrials.gov (NCT02058589). 
Anonymized individual participant data and study documents 
can be requested for further research at www.clinicalstudy-
datarequest.com.
Study Vaccine
Study participants received 2 intramuscular doses of RZV or 
placebo 1–2M apart in a deltoid muscle. Each 0.5-mL dose of 
RZV contained 50 μg of recombinant VZV gE antigen and the 
GSK proprietary AS01B Adjuvant System (containing 50 μg 
of 3-O-desacyl-4’-monophosphoryl lipid A, 50 μg of Quillaja 
saponaria Molina, fraction 21 [QS21, licensed by GSK from 
Antigenics LLC, a wholly owned subsidiary of Agenus Inc, a 
Delaware, USA corporation], and liposome). Each 0.5-mL dose 
of placebo contained 20 mg lyophilized sucrose reconstituted 
with 150 mM sodium chloride solution.
Assessment of Immunogenicity
Humoral immunogenicity was assessed from blood samples col-
lected from each participant at prevaccination (M0 visit), 1–2M 
post–dose 1 (M1 visit), 1M post–dose 2 (M2 visit), 6M post–
dose 2 (M7 visit), and 12M post–dose 2 (M13). Anti-gE anti-
body concentrations were measured by anti-gE enzyme-linked 
immunosorbent assay with a technical cutoff of assay quantifica-
tion of 97 mIU/mL. Cell-mediated immunogenicity (CMI) was 
evaluated in a subset of participants at the M0, M2, and M13 
visits. The frequencies of gE-specific CD4[2+] T cells (CD4 +  
T-cells expressing at least 2 activation markers of the 4 markers 
assessed: interferon-γ, interleukin 2, tumor necrosis factor–α, 
and CD40 ligand) were measured, after in vitro stimulation with 
a pool of peptides covering the gE ectodomain, by intracellular 
cytokine staining and detection by flow cytometry as described 
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previously [20]. The cutoff for the CMI vaccine response anal-
ysis was 320 positive cells per 106 CD4 +  T cells counted.
Assessment of Reactogenicity and Safety
Diary cards were provided to all participants to record solicited 
local (pain, redness, and swelling at the injection site) and ge-
neral (fever [body temperature ≥37.5°C/99.5°F], headache, fa-
tigue, gastrointestinal symptoms [nausea, vomiting, diarrhea, 
and/or abdominal pain], myalgia, and shivering) adverse events 
(AEs) during 7 days (D) after each vaccination, and unsolicited 
AEs during 30D after each vaccination. Solicited general AEs, 
as well as unsolicited AEs, were also recorded during 7D be-
fore first vaccination to evaluate the baseline values resulting 
from the underlying condition of participants. AEs were graded 
from 0 (none/normal) to 3 (severe). Grade 3 AEs were defined 
as preventing normal activity (for all unsolicited AEs, and for 
headache, fatigue, gastrointestinal symptoms, myalgia, and 
shivering), as significant pain at rest, and preventing normal 
everyday activities (for pain) and having a surface diameter 
>100 mm (for injection-site redness and swelling).
All solicited local AEs were considered causally related to 
vaccination. The causal relationship to vaccination of all other 
AEs occurring postvaccination was assessed by the investigator. 
Allograft function (by routine serum creatinine measurements) 
was reported from first vaccination to study end.
Serious AEs (SAEs), including biopsy-proven allograft rejec-
tions, and pIMDs were recorded from first vaccination to M13. 
In addition, SAEs related to study participation were recorded 
from enrollment to study end. If a clinical event was suspicious 
for HZ per the investigator’s judgement, it was considered a sus-
pected case of HZ. Suspected cases and HZ complications were 
recorded from first vaccination to study end and constituted 
AEs/SAEs, as appropriate.
Outcomes
Study objectives and their evaluation criteria are presented in 
Table 1.
Statistical Analyses
Safety and reactogenicity were assessed in the total vaccinated 
cohort (TVC), which included all participants with at least 1 
administered/documented vaccine dose. The analysis of hu-
moral immunogenicity during the vaccination (up to M2) and 
persistence (up to M13) phases were performed on the appli-
cable according-to-protocol cohorts, which included all partici-
pants who complied with the protocol-specified procedures and 
for whom data were available. The analysis of gE-specific CMI 
during the vaccination and persistence phases was performed 
on the applicable according-to-protocol cohorts of the CMI 
subcohort, which included the first enrolled participants from 
designated sites that had access to a GSK-validated peripheral 
blood mononuclear cell processing facility. Further details on 
statistical methods, including sample size calculation, are pro-
vided in Supplementary Text 2.
Table 1. Study Objectives
No. Objective Success Criterion
Primary objectives
I To evaluate VRR for the anti-gE humoral immune response at M2, following 
2 doses of RZV in all participants.
The objective was met if the LL of the 95% CI of the VRRa for anti-gE 
antibody concentrations at M2 in the RZV group was ≥60%.
II To evaluate the safety of RZV, as compared to placebo, from first  vaccina-
tion until 30 days after last vaccination in all participants.
Descriptive
Secondary objectives
III To evaluate the anti-gE humoral immune response at M2, following 2 doses 
of RZV, as compared to placebo, in all participants.
The objective was met if the LL of the 95% CI of the geometric mean 
ratio (RZV over placebo) of anti-gE concentrations at M2 was >3.
IV To characterize anti-gE humoral immune responses at M0, M1, M2, M7, 
and M13, within the RZV and placebo groups, in all participants.
Descriptive
V To evaluate VRR for gE-specific CD4 +  T-cell–mediated immune responses 
at M2, following a 2-dose administration of the RZV, in the CMI subcohort.
The objective was met if the LL of the 95% CI of the VRRb for gE-spe-
cific CD4[2+] T-cell frequencies at M2 in the RZV group was ≥50%.
VI To evaluate gE-specific CD4 +  T-cell–mediated immune response at M2 fol-
lowing 2 doses of RZV, as compared to placebo, in the CMI subcohort.
The objective was met if the LL of the 95% CI of the geometric mean 
ratio (RZV over placebo) of gE-specific CD4[2+] T-cell frequencies at 
M2 was >1.
VII To characterize gE-specific CD4 +  T-cell–mediated immune responses at 
M0, M2, and M13, within the RZV and placebo groups, in the CMI subco-
hort.
Descriptive
VIII To evaluate the safety of the vaccine, as compared to placebo, from 30 
days after last vaccination until study end in all participants.
Descriptive
Abbreviations: CD4[2+], CD4 +  T cells expressing at least 2 activation markers of the 4 markers assessed (interferon-γ, interleukin 2, tumor necrosis factor–α, and CD40 ligand); CI, confi-
dence interval; CMI, cell-mediated immunogenicity; gE, glycoprotein E; LL, lower limit; M, study month; placebo, participants receiving placebo; RZV, participants receiving the recombinant 
adjuvanted herpes zoster vaccine; VRR, vaccine response rate.
aVRR in terms of anti-gE humoral response was defined as the percentage of participants with postvaccination anti-gE concentrations (i) ≥4-fold the technical cutoff of assay quantification 
(for initially seronegative participants) or (ii) ≥4-fold the prevaccination concentration (for initially seropositive participants).
bVRR in terms of CD4[2+] T-cell response was defined as the percentage of participants with postvaccination CD4[2+] T-cell frequencies ≥2-fold the cutoff (320 positive cells per 106 CD4 +  
T cells counted) (for participants initially below the cutoff) or ≥2-fold the prevaccination CD4[2+] T-cell frequencies (for participants initially above the cutoff).
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RESULTS
Study Participants
A total of 264 RT patients (RZV: 132, placebo: 132) were in-
cluded in the TVC. Of these, 260 (RZV: 130, placebo: 130) 
participated through to the last study visit at M13 (Figure 1). 
Demographic characteristics were balanced between study 
groups (Table 2). At dose 1, the mean ages were 52.3 and 52.4 
years in the RZV and placebo groups, respectively. Most partici-
pants were male (RZV: 71.2%, placebo: 68.9%) and white (RZV: 
66.7%, placebo: 73.5%).
Immunogenicity
Humoral Immunogenicity
Both confirmatory objectives on humoral immunogenicity 
were met: The humoral vaccine response rate (VRR) in the RZV 
group was 80.2% (95% confidence interval [CI], 71.9%–86.9%) 
at M2 (success criterion: lower limit [LL] of 95% CI ≥60%), and 
the adjusted anti-gE antibody geometric mean concentration 
(GMC) ratio (RZV over placebo) was 14.00 (95% CI, 10.90–
17.99; P < .0001) at M2 (success criterion: LL of 95% CI >3) 
(Figure 2).
Among RZV recipients, anti-gE antibody GMCs increased 
from 1354.4 mIU/mL (95% CI, 1118.3–1640.4 mIU/mL) at 
prevaccination to 19 163.8 mIU/mL (95% CI, 15 041.5–24 416.0 
mIU/mL) at M2 and persisted through M13 at 8545.1 mIU/mL 
(95% CI, 6753.7–10 811.5 mIU/mL). Postvaccination anti-gE 
antibody GMCs and humoral VRRs in the placebo group 
remained near the prevaccination level. Across time points, 
no apparent differences in anti-gE antibody GMCs were seen 
linked to the types of maintenance immunosuppressive therapy 
(Supplementary Table 2). At each time point, humoral im-
mune responses appeared higher in the 18–49 years of age co-
hort than in the ≥50 years of age cohort (Figure 2). Within the 
18–49 years of age cohort, post hoc analyses revealed humoral 
immune responses similar for ages 18–29 and 30–49 years 
(Supplementary Table 3).
Figure 1. Participant flowchart. Abbreviations: AE, adverse event; ATP, according to protocol; CMI, cell-mediated immunogenicity; M, study month; n, number of partici-
pants in each category; pIMD, potential immune-mediated disease; Placebo, participants receiving placebo; RZV, participants receiving the recombinant adjuvanted herpes 
zoster vaccine; SAE, serious adverse event; TVC, total vaccinated cohort.
RZV in Renal Transplant Recipients • cid 2020:70 (15 January) • 185
Cell-mediated Immunogenicity
Though CMI was measured in a limited subset of participants, 
both confirmatory CMI objectives were met: The VRR for CMI 
responses was 71.4% (95% CI, 51.3%–86.8%) in the RZV group 
at M2 (success criterion: LL of 95% CI ≥50%) (Figure 3); the ge-
ometric mean ratio (RZV over placebo) of gE-specific CD4[2+] 
T-cell frequencies was 17.26 (95% CI, 5.92–50.36; P < .0001) at 
M2 (success criterion: LL of 95% CI >1).
At prevaccination, median CD4[2+] T-cell frequencies were 
21.2 and 59.7 in the RZV and placebo groups, respectively. In 
the RZV group, median frequencies increased to 2149.0 at M2 
and remained significantly elevated over prevaccination base-
line at M13. Postvaccination CD4[2+] T-cell frequencies and 
CMI VRRs in the placebo group remained near the prevacci-
nation level. At each time point, CMI responses appeared to 
be higher in the 18–49 years of age cohort (Figure 3). Within 
the 18–49 years of age cohort, post hoc analyses revealed CMI 
responses similar for the age 18–29 and 30–49 years of age 
groups (Supplementary Table 4).
Reactogenicity and Safety
During the 7D postvaccination period, injection site pain was the 
most frequent solicited local symptom, reported by 114 (87.0%) of 
RZV and 11 (8.3%) of placebo participants (Figure 4). Solicited local 
symptoms in RZV recipients had a median duration of 4D or less.
During the 7D postvaccination period, myalgia and fever 
were reported at higher rates by RZV compared to placebo par-
ticipants. Myalgia was reported by 65 (49.6%) RZV participants 
and by 31 (23.5%) placebo participants; and fever by 21 (16.0%) 
RZV participants and 5 (3.8%) placebo participants (Figure 
4). Myalgia, shivering, and fever appeared to be more fre-
quently reported post- than prevaccination in the RZV group 
(Supplementary Figure 1B and 1C).
During the 7D prevaccination period, at least 1 unsolicited 
symptom was reported by 9 (6.8%) RZV participants and 7 
(5.3%) placebo participants. No grade 3 unsolicited AEs were 
reported in either study group during this time period.
During the longer, 30D postvaccination period, at least 1 un-
solicited symptom (any grade) was reported by 51 (38.6%) RZV 
participants and 44 (33.3%) placebo participants. Grade 3 unso-
licited symptoms were reported by 7 (5.3%) RZV and 5 (3.8%) 
placebo participants (Table 3).
From first vaccination through M13, SAEs were reported 
by 26 (19.7%) RZV and 33 (25.0%) placebo participants. Of 
these, 3 SAEs (febrile neutropenia, mucosal inflammation, 
and Burkitt lymphoma) were considered as causally related to 
vaccination and were reported by 1 placebo recipient. Overall, 
the most frequent SAEs classified by Medical Dictionary for 
Regulatory Activities System Organ Class were “infections and 
infestations.”
Table 2. Summary of Demographic Characteristics (Total Vaccinated Cohort)
Characteristic Parameter or Category
RZV 
(N = 132)
Placebo 
(N = 132)
Age at dose 1, y Mean ± SD 52.3 ± 12.5 52.4 ± 12.8
Gender Female 38 (28.8) 41 (31.1)
Male 94 (71.2) 91 (68.9)
Age group 18–49 y 48 (36.4) 49 (37.1)
≥50 y 84 (63.6) 83 (62.9)
Geographic ancestry White–Caucasian/European heritage 88 (66.7) 97 (73.5)
Asian–East Asian heritage 20 (15.2) 22 (16.7)
 Asian–South East Asian heritage 10 (7.6) 3 (2.3)
African heritage/African American 3 (2.3) 1 (0.8)
 White–Arabic/North African heritage 2 (1.5) 2 (1.5)
Asian–Central/South Asian heritage 1 (0.8) 2 (1.5)
 Asian–Japanese heritage 0 (0.0) 1 (0.8)
Other 8 (6.1) 4 (3.0)
PRA/cPRA score 0%–19% 117 (88.6) 117 (88.6)
20%–79% 13 (9.8) 12 (9.1)
 80%–100% 2 (1.5) 3 (2.3)
Immunosuppressive therapy CIS + CS + MC 100 (75.8) 102 (77.3)
 CIS + MC 23 (17.4) 22 (16.7)
CIS + CS 7 (5.3) 8 (6.1)
 Other combinationsa 2 (1.5) 0 (0.0)
Data are presented as no. (%) except for the ‘Age at dose 1’ data.
Abbreviations: CIS, calcineurin inhibitor or sirolimus; cPRA, calculated panel reactive antibody; CS, corticosteroids; MC, mycophenolate compound; N, number of vaccinated participants; 
placebo, participants receiving placebo; PRA, panel reactive antibody; RZV, participants receiving the recombinant adjuvanted herpes zoster vaccine; SD, standard deviation.
aOther immunosuppressive combinations are not included in the table secondary to small sample size.
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Throughout the entire study, 1 fatality (0.8%) was reported in 
each of the study groups (RZV: purulent meningitis; placebo: 
coronary artery disease complicated by vein graft thrombosis 
and myocardial infarction; Table 3). Neither was considered 
causally related to vaccination by the investigator.
No biopsy-proven renal allograft rejections occurred from 
first vaccination up to 30D after the last dose in either group. 
Throughout the entire study, 4 (3.0%) and 7 (5.3%) biop-
sy-proven rejections occurred in the RZV and placebo groups, 
respectively (Table 3). Of these, 1 in the RZV group and all 7 in 
the placebo group occurred in participants with low rejection 
risk based on PRA/cPRA predictions (PRA/cPRA, 0–19%).
Serum creatinine level increases >1.5-fold were detected in 4 
(3.1%) of RZV and 4 (3.0%) of placebo recipients. Percentages 
of participants with >1.75-fold or >2-fold increases were also 
similar in the 2 study groups (Table 3).
No pIMDs were reported from first vaccination up to 30D 
after the last dose in either group. Through M13, pIMDs were 
reported by 4 (3.0%) RZV and 2 (1.5%) placebo participants 
(Table 3).
In the TVC, 3 (2.3%) RZV recipients and 7 (5.3%) pla-
cebo participants reported suspected HZ episodes. One of the 
episodes occurred in a participant who had not yet received 
both RZV doses.
DISCUSSION
Our study demonstrates that RZV was immunogenic in RT 
patients aged ≥18 years under chronic daily immunosuppression. 
Humoral and cellular immune responses to vaccination persisted 
through 1 year after vaccination. No safety concerns were identi-
fied in this study. A results summary contextualizing the results 
and potential clinical relevance is provided in Figure 5 to assist 
communications to the patient.
RZV induced robust humoral and cell-mediated immune 
responses to gE when administered 4–18M after RT. Vaccination 
took place when RT maintenance immunosuppression levels were 
achieved, and prior to the rise of HZ incidence in this population. 
As seen in other RZV trials in immunocompromised populations 
such as autologous HSCT recipients [19], patients with solid tumors 
[21], and patients with hematologic malignancies [16], RZV was 
found to be immunogenic as shown by high VRR for both humoral 
and cellular immune responses, as well as by anti-gE antibody GMC 
ratios and CD4[2+] T-cell frequency ratios.
Figure 2. Humoral immune responses (according-to-protocol cohort for humoral immunogenicity). A, Anti-gE antibody geometric mean concentration; B, humoral vaccine 
response rate. Vaccine response rate in terms of anti–glycoprotein E (gE) humoral response was defined as the percentage of participants with postvaccination anti-gE 
concentrations (i) ≥4-fold the technical cutoff of assay quantification (for initially seronegative participants) or (ii) ≥4-fold the prevaccination concentration (for initially sero-
positive participants). Abbreviations: GMC, geometric mean concentration; M, study month; N, number of participants in the according-to-protocol cohort for humoral immu-
nogenicity; Placebo, participants receiving placebo; RZV, participants receiving the recombinant adjuvanted herpes zoster vaccine; VRR, vaccine response rate.
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Figure 3. Cell-mediated immune responses (according-to-protocol cohort for cell-mediated immunogenicity). A, CD4[2+] T-cell frequencies; B, cell-mediated vaccine re-
sponse rate. Vaccine response rate in terms of CD4[2+] T-cell response was defined as the percentage of participants with postvaccination CD4[2+] T-cell frequencies (i) 
≥2-fold the cutoff (320 positive cells per 106 CD4 +  T cells counted) (for participants initially below the cutoff) or (ii) ≥2-fold the prevaccination CD4[2+] T-cell frequencies (for 
participants initially above the cutoff). Abbreviations: CD4[2+], CD4 +  T cells expressing at least 2 activation markers of the 4 markers assessed (interferon-γ, interleukin 2, 
tumor necrosis factor–α, and CD40 ligand); CMI, cell-mediated immunogenicity; M, study month; N, number of participants in the according-to-protocol cohort for cell-me-
diated immunogenicity; Placebo, participants receiving placebo; RZV, participants receiving the recombinant adjuvanted herpes zoster vaccine; VRR, vaccine response rate.
Figure 4. Reactogenicity in the total vaccinated cohort. Error bars indicate 95% confidence intervals. Fever was defined as body temperature ≥37.5°C. Abbreviations: GI, 
gastrointestinal symptoms (nausea, vomiting, diarrhea, and/or abdominal pain); N, number of participants with at least 1 documented vaccine administration; Placebo, par-
ticipants receiving placebo; RZV, participants receiving the recombinant adjuvanted herpes zoster vaccine. *Fever was not graded in this study. For fever, body temperatures 
>39°C are presented as grade 3.
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Anti-gE antibody GMCs and humoral VRRs at 1M and 12M 
post–dose 2 were in similar ranges with those in autologous 
HSCT recipients ≥18 years of age [19]. In this study, both RZV-
induced humoral and cellular immune responses appeared to 
be higher in the younger (18–49 years of age) compared to the 
older (≥50 years of age) age groups across all time points. In 
the older age group of this study, humoral GMCs and VRRs, as 
well as CMI VRRs, at 1M and 12M post–dose 2 were lower than 
in immunocompetent adults of the same age [20]. However, 
gE-specific CD4[2+] T-cell frequencies at 1M and 12M post–
dose 2 in the older age group were in similar ranges with those 
in immunocompetent adults ≥50 years of age [20]. As VZV-
specific cellular immunity is believed to be the main mecha-
nistic driver of protection against HZ [22], RZV vaccination 
is expected to reduce the risk of HZ in RT recipients [14, 15]. 
The responses of adults ≥50 years of age in our study are likely 
a result of the combined effects of immunosenescence and the 
use of maintenance immunosuppressive therapy.
Though the number of participants in each subgroup was 
low, our results indicate that RZV-induced humoral immune 
responses were similar in range across the different immuno-
suppressive regimens assessed.
In line with the reactogenicity profile of RZV in the piv-
otal phase 3 efficacy trials, RZV recipients reported solicited 
local symptoms more frequently than placebo recipients [14, 
15]. Compared to placebo, the frequency of solicited general 
symptom reporting by RZV recipients increased only for my-
algia after dose 1 and for myalgia, shivering, and fever after dose 
2. Solicited AEs were primarily mild to moderate and transient 
in nature. In the RZV group, only 1 participant (<1%) withdrew 
from the study before receiving dose 2, due to an AE (fever) that 
persisted for 2 days after receiving RZV dose 1.
Table 3. Safety and Reactogenicity (Total Vaccinated Cohort)
 RZV (N = 132a) Placebo (N = 132)
AEs No. % (95% CI) No. % (95% CI)
Reported during the 7D prevaccination period 
 Unsolicited AEs Any grade 9 6.8 (3.2–12.5) 7 5.3 (2.2–10.6)
Grade 3 0 — 0 —
Reported during the 7D postvaccination period 
 Solicited local AEs Any grade 115 87.8 (80.9–92.9) 12 9.1 (4.8–15.3)
 Grade 3 14 10.7 (6.0–17.3) 0 0 (0–2.8)
 Solicited general AEs Any grade 90 68.7 (60.0–76.5) 73 55.3 (46.4–64.0)
 Grade 3 13 9.9 (5.4–16.4) 11 8.3 (4.2–14.4)
Reported during the 30D postvaccination period 
 Unsolicited AEs Any grade 51 38.6 (30.3–47.5) 44 33.3 (25.4–42.1)
Grade 3 7 5.3 (2.2–10.6) 5 3.8 (1.2–8.6)
 Relatedb–any grade 7 5.3 (2.2–10.6) 3 2.3 (0.5–6.5)
With medically attended visits 34 25.8 (18.5–34.1) 29 22.0 (15.2–30.0)
Reported from first vaccination up to 30D after last vaccination 
 SAEs All 6 4.5 (1.7–9.6) 5 3.8 (1.2–8.6)
 Biopsy-proven allograft rejection 0 0 0 0
 pIMDs All 0 — 0 —
Reported from 30D after last vaccination up to study end 
 SAEs All 21 15.9 (10.1–23.3) 29 22.0 (15.2–30.0)
 Biopsy-proven allograft rejection 4 3.0 7 5.3
 pIMDs All 4 3.0 (0.8–7.6) 2 1.5 (0.2–5.4)
Reported from first vaccination up to study end
 SAEs At least 1 symptom 26 19.7 (13.3–27.5) 33 25.0 (17.9–33.3)
 Relatedb 0 0 (0.0–2.8) 1 0.8 (0.0–4.1)
Fatal 1 0.8 1 0.8
 pIMDs At least 1 symptom 4 3.0 (0.8–7.6) 2 1.5 (0.2–5.4)
 Serum creatinine increase >1.5-fold 4 3.1 4 3.0
 >1.75-fold 3 2.3 2 1.5
>2-fold 2 1.5 1 0.8
Data are overall/participant. No. and % indicate the number and percentage of participants reporting at least 1 event; N indicates the number of participants with at least 1 documented 
(solicited AEs) or administered (other AEs) dose.
Abbreviations: AE, adverse event; CI, confidence interval; D, days; pIMD, potential immune-mediated disease; Placebo, participants receiving placebo; RZV, participants receiving the recom-
binant adjuvanted herpes zoster vaccine; SAE, serious adverse event. 
aFor the 7D postvaccination period and for creatinine fold increase (N = 131). 
bRelated indicates potentially causally related to vaccination per investigator assessment.
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Overall, no apparent differences were observed between 
study groups in the occurrence of unsolicited AEs, SAEs (in-
cluding fatalities), pIMDs, biopsy-proven allograft rejections, 
or allograft function changes. Overall, the reported events are 
consistent with the background disease or concomitant med-
ications. Indeed, RZV does not impact allograft function, as 
observed through creatinine measurements or rejection rate. A 
lower rate of suspected HZ cases was reported in RZV vs pla-
cebo recipients (3 vs 7 suspected cases).
Taken together with the clinically acceptable safety profile, 
the benefit-risk profile of RZV in RT recipients appears favor-
able, though vaccine effectiveness in this population has not 
been established.
Our results should be interpreted considering the study’s 
strengths and limitations. Study strengths include the fact that 
randomization was performed using several minimization fac-
tors leading to comparable baseline characteristics between the 
2 study groups. Considering the high rate of solicited general 
AEs in the RT population, these were also recorded for 7D be-
fore vaccination, to indicate the increase of such AEs due to vac-
cination. Renal allograft function and rejections were followed 
up for 1 year. As the study was carried out in a limited number 
of geographic regions, the racial heterogeneity was not very 
broad. However, in an earlier study, race did not appear to im-
pact RZV immunogenicity [20]. Furthermore, the analysis by 
age and by immunosuppressive treatment regimen should be 
interpreted with caution as the number of participants in each 
of these subgroups was low. While this study was not designed 
to establish the immunologic correlates of protection or deter-
mine the vaccine efficacy in this population, the study’s safety 
profile and robust immune responses suggest a favorable bene-
fit-risk assessment for RZV in RT recipients.
In conclusion, RZV was immunogenic in RT recipients re-
ceiving daily immunosuppressive therapy. Humoral and cel-
lular immunogenicity persisted through the 1-year evaluation, 
while no vaccine-related concerns were identified. No apparent 
differences were observed between RZV and placebo recipients 
for allograft function and rejections.
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